evaluation of aryoseven safety (recombinant activated factor vii) in patients with bleeding disorders (an observational post-marketing surveillance study)

نویسندگان

gholamreza toogeh

thromboses hemostasis research center, tehran university of medical sciences, tehran, iran hassan abolghasemi

pediatric congenital hematologic disorders research center, shahid beheshti university of medical sciences, tehran, iran peyman eshghi

pediatric congenital hematologic disorders research center, shahid beheshti university of medical sciences, tehran, iran mohammadreza managhchi

thromboses hemostasis research center, tehran university of medical sciences, tehran, iran mohammadreza shaverdi-niasari

چکیده

background: recombinant activated factor vii induces hemostasis in patients with coagulopathy disorders. aryoseven™ as a safe iranian recombinant activated factor vii has been available on our market. this study was performed to establish the safety of aryoseven on patients with coagulopathy disorder. methods: this single-center, descriptive, cross sectional study was carried out in thrombus and homeostasis research center valiasr hospital during 2013-2014. fifty one patients with bleeding disorders who received at least one dose of aryoseven were enrolled. patients’ demographic data and adverse effect of drug and reaction related to aryoseven or previous usage of recombinant activated fvii were recorded in questionnaires. finally data were analyzed to compare side effects of aryoseven and other recombinant activated fvii brands. results: aryoseven was prescribed for 51 patients. of all participants with mean age 57.18+21.38 yr, 31 cases were male and 26 subjects had past history of recombinant activated fvii usage. glanzman was the most frequent disorder followed by congenital fvii deficiency, hemophilia with inhibitors, factor 5 deficiency, acquired hemophilia, hemophilia a with inhibitor, and hemophilia a or b with inhibitor. the majority of bleeding episodes had occurred in joints. three patients (5.9%) complained about adverse effects of aryoseven vs. 11.5 % about adverse effects of other brands. however this difference was not significant, statistically. conclusion: based on monitor patients closely for any adverse events, we concluded that aryoseven administration under careful weighing of benefit versus potential harm may comparable with other counterpart drugs.   how to cite this article: toogeh g, abolghasemi h, eshghi p, managhchi m, shaverdi-niasari m, karimi k, et al. evaluation of aryoseven safety (recombinant activated factor vii) in patients with bleeding disorders (an observational post-marketing surveillance, study). iran j pathol. 2016; 11(3):204-9.

برای دانلود باید عضویت طلایی داشته باشید

برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

منابع مشابه

Evaluation of Aryoseven Safety (Recombinant Activated Factor VII) in Patients with Bleeding Disorders (An Observational Post-Marketing Surveillance Study)

Background: Recombinant activated factor VII induces hemostasis in patients with coagulopathy disorders. AryoSeven™ as a safe Iranian Recombinant activated factor VII has been available on our market. This study was performed to establish the safety of AryoSeven on patients with coagulopathy disorder. Methods: This single-center, descriptive,...

متن کامل

Evaluation of Aryoseven Safety (Recombinant Activated Factor VII) in Patients with Bleeding Disorders (An Observational Post-Marketing Surveillance Study).

BACKGROUND Recombinant activated factor VII induces hemostasis in patients with coagulopathy disorders. AryoSeven™ as a safe Iranian Recombinant activated factor VII has been available on our market. This study was performed to establish the safety of AryoSeven on patients with coagulopathy disorder. METHODS This single-center, descriptive, cross sectional study was carried out in Thrombus an...

متن کامل

Recombinant activated factor VII for bleeding in patients without inherited bleeding disorders.

(1) Recombinant activated factor VII (rFVIIa) is licensed in Canada for the prevention and treatment of bleeding in hemophiliacs, but it is increasingly used to control bleeding in non-hemophilic patients during surgery, or during treatment for severe trauma or intracerebral hemorrhage (ICH). (2) In one clinical trial, there was a significant reduction in mortality among patients with ICH treat...

متن کامل

Cost-Effectiveness Analysis of Biogeneric Recombinant Activated Factor VII (AryoSeven™) and Activated Prothrombin Complex Concentrates (FEIBA™) to Treat Hemophilia A Patients with Inhibitors in Iran

Abstract Nowadays, bypassing agents such as recombinant activated factor VII (rFVIIa) and activated prothrombin complex concentrates (aPCC) are used to treat bleeding episodes in the Hemophilia patients with inhibitors. AryoSeven® is an Iranian biogeneric rFVIIa with homogeneity of efficacy and the nature to NovoSeven in a comparative trial. The current clinical trial aimed to evaluate the cost...

متن کامل

Cost-Effectiveness Analysis of Biogeneric Recombinant Activated Factor VII (AryoSeven™) and Activated Prothrombin Complex Concentrates (FEIBA™) to Treat Hemophilia A Patients with Inhibitors in Iran

Abstract Nowadays, bypassing agents such as recombinant activated factor VII (rFVIIa) and activated prothrombin complex concentrates (aPCC) are used to treat bleeding episodes in the Hemophilia patients with inhibitors. AryoSeven® is an Iranian biogeneric rFVIIa with homogeneity of efficacy and the nature to NovoSeven in a comparative trial. The current clinical trial aimed to evaluate the cost...

متن کامل

Successful Control of Massive Bleeding in a Child with Burkitt's Lymphoma via a Biosimilar Recombinant Activated Factor VII (AryoSeven™)

We describe a case of a 4-year-old girl with Burkitt's lymphoma, who suffered from a massive gastrointestinal hemorrhage 3 days after chemotherapy. In spite of applying the common practice in correction of coagulopathy, thrombocytopenia persisted and bleeding became life-threatening. In the present case report, we report a successful control of bleeding with a single-dose administration of a bi...

متن کامل

منابع من

با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید


عنوان ژورنال:
iranian journal of pathology

جلد ۱۱، شماره ۳، صفحات ۲۰۴-۲۰۹

کلمات کلیدی

میزبانی شده توسط پلتفرم ابری doprax.com

copyright © 2015-2023